Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3984191
Max Phase: Preclinical
Molecular Formula: C48H54ClN7O8S
Molecular Weight: 924.52
Molecule Type: Small molecule
Associated Items:
ID: ALA3984191
Max Phase: Preclinical
Molecular Formula: C48H54ClN7O8S
Molecular Weight: 924.52
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CCC(N4CCOCC4)C3)CC2)cc1Oc1ccc2[nH]ccc2c1
Standard InChI: InChI=1S/C48H54ClN7O8S/c49-37-3-1-34(2-4-37)42-9-5-38(55-21-25-63-26-22-55)27-36(42)32-53-17-19-54(20-18-53)39-6-10-43(47(29-39)64-40-7-11-44-35(28-40)13-16-50-44)48(57)52-65(60,61)41-8-12-45(46(30-41)56(58)59)51-31-33-14-23-62-24-15-33/h1-4,6-8,10-13,16,28-30,33,38,50-51H,5,9,14-15,17-27,31-32H2,(H,52,57)
Standard InChI Key: KQYJGMPTUNIRII-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 924.52 | Molecular Weight (Monoisotopic): 923.3443 | AlogP: 7.94 | #Rotatable Bonds: 14 |
Polar Surface Area: 171.61 | Molecular Species: ACID | HBA: 12 | HBD: 3 |
#RO5 Violations: 3 | HBA (Lipinski): 15 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 4.18 | CX Basic pKa: 8.01 | CX LogP: 6.26 | CX LogD: 5.95 |
Aromatic Rings: 5 | Heavy Atoms: 65 | QED Weighted: 0.07 | Np Likeness Score: -1.08 |
1. (2015) Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases, |
Source(1):